GlassScriptPhysician profile
Carley Edwards
NPI 1053044719
$1,072.69
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.93 · 2023: $518 · 2024: $293 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $189.08 | 2023-2024 | Farxiga |
| Vifor Pharma, INC. | $153.84 | 2023-2025 | Veltassa, Korsuva |
| Vantive US Healthcare LLC | $121.85 | 2025 | Renal - Acute |
| Amgen INC. | $115.98 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.10 | 2023-2024 | |
| Daiichi Sankyo INC. | $102.71 | 2023 | Injectafer |
| Ardelyx, INC. | $61.76 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $48.06 | 2024-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.15 | 2024-2025 | Jardiance |
| Abbvie INC. | $36.80 | 2023 | |
| W. L. Gore & Associates, INC. | $29.77 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Otsuka America Pharmaceutical, INC. | $21.12 | 2025 | Jynarque |
| Organon LLC | $18.93 | 2022 | |
| Novo Nordisk INC | $14.54 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carley Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.